(Q38341953)

2 September 2017

1 reference

title

Treatment of pulmonary arterial hypertension in children (English)

1 reference

2 September 2017

main subject

arterial hypertension

0 references

2

Tammo Delhaas

1 reference

2 September 2017

Heiner Latus

1

1 reference

2 September 2017

Dietmar Schranz

series ordinal

3

1 reference

2 September 2017

Christian Apitz

series ordinal

4

1 reference

2 September 2017

language of work or name

English

0 references

publication date

3 February 2015

1 reference

Nature Reviews Cardiology

2 September 2017

published in

1 reference

2 September 2017

volume

12

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

244-254

1 reference

Guidelines for the diagnosis and treatment of pulmonary hypertension.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Clinical features of paediatric pulmonary hypertension: a registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Childhood idiopathic pulmonary arterial hypertension: a national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Potts shunt and atrial septostomy in pulmonary hypertension caused by left ventricular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Creation of a functional Potts shunt by stenting the persistent arterial duct in newborns and infants with suprasystemic pulmonary hypertension of various etiologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pulmonary vascular disease in adults with congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pediatric pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Outcomes in children with idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Vasodilator therapy for primary pulmonary hypertension in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pulmonary arterial hypertension in France: results from a national registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Assessment of pulmonary endothelial function during invasive testing in children and adolescents with idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Updated treatment algorithm of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pulmonary arterial hypertension: a comparison between children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

The endothelin system in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Bosentan in pediatric patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Effects of long-term bosentan in children with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Safety of sildenafil in infants*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Paediatric pulmonary hypertension and sildenafil: current practice and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Initial experience with tadalafil in pediatric pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

New trial designs and potential therapies for pulmonary artery hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Macitentan and morbidity and mortality in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Riociguat for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Novel and emerging therapies for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Treatment of group I pulmonary arterial hypertension with carvedilol is safe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Safety and efficacy of exercise training in various forms of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Atrial septostomy improves survival in select patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Interventional and surgical modalities of treatment in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Atrial septostomy in patients with pulmonary hypertension: should it be recommended?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Atrial septostomy for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

A modelling study of atrial septostomy for pulmonary arterial hypertension, and its effect on the state of tissue oxygenation and systemic blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Interventional and surgical modalities of treatment for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Anatomical considerations for the development of a new transcatheter aortopulmonary shunt device in patients with severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Stenting of the ductus arteriosus and banding of the pulmonary arteries: basis for various surgical strategies in newborns with multiple left heart obstructive lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Stent implantation in the ductus arteriosus for pulmonary blood supply in congenital heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Hybrid transcatheter-surgical palliation: basis for univentricular or biventricular repair: the Giessen experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Stenting of the arterial duct and banding of the pulmonary arteries: basis for combined Norwood stage I and II repair in hypoplastic left heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Patent ductus arteriosus stenting (transcatheter Potts shunt) for palliation of suprasystemic pulmonary arterial hypertension: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Potts shunt in a child with end-stage pulmonary hypertension after late repair of ventricular septal defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Multiple Left Heart Obstructions (Shone’s Anomaly) With Mitral Valve Involvement: Long-Term Surgical Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Outcomes of reparative and transplantation strategies for multilevel left heart obstructions with mitral stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Hypoplastic left heart syndrome with intact or highly restrictive atrial septum: outcome after neonatal transcatheter atrial septostomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Hypoplastic left heart syndrome with intact or highly restrictive atrial septum: surgical experience from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Biventricular response after pulmonary valve replacement for right ventricular outflow tract dysfunction: is age a predictor of outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Right versus left ventricular failure: differences, similarities, and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Biventricular structural and functional responses to aortic constriction in a rabbit model of chronic right ventricular pressure overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pulmonary artery banding in infants and young children with left ventricular dilated cardiomyopathy: a novel therapeutic strategy before heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Lung and Heart-Lung Transplantation Report--2013; focus theme: age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

OPTN/SRTR 2011 Annual Data Report: lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Lung transplantation in children with idiopathic pulmonary arterial hypertension: an 18-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Clinical trials in neonates and children: Report of the pulmonary hypertension academic research consortium pediatric advisory committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Liver toxicity of sitaxentan in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

21 January 2018

Pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Potts shunt in patients with pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Potts anastomosis for children with idiopathic pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Bosentan therapy for pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

A new START for Sildenafil in pediatric pulmonary hypertension: reframing the dose-survival relationship in the STARTS-2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

β-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Prognosis for patients with Eisenmenger syndrome of various aetiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Atrial septostomy decreases sympathetic overactivity in pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Increased sympathetic nerve activity in pulmonary artery hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Echocardiographic Evaluation of Patients with Primary Pulmonary Hypertension Before and After Atrial Septostomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

The effect of atrial septostomy on the concentration of brain-type natriuretic peptide in patients with idiopathic pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Anastomosis of the aorta to a pulmonary artery; certain types in congenital heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Radiofrequency perforation may increase the safety of transcatheter Potts shunt creation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Fifteen-year single center experience with the "Giessen Hybrid" approach for hypoplastic left heart and variants: current strategies and outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Stent implantation of the arterial duct in newborns with a truly duct-dependent pulmonary circulation: a single-center experience with emphasis on aspects of the interventional technique

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Surgical palliation of primary pulmonary arterial hypertension by a unidirectional valved Potts anastomosis in an animal model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Outcome of biventricular repair in infants with multiple left heart obstructive lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

The hypoplastic left heart syndrome with intact atrial septum: atrial morphology, pulmonary vascular histopathology and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Right ventricular failure from severe pulmonary hypertension after surgery for shone complex: back to fetal physiology with reducting, atrioseptectomy, and bilateral pulmonary arterial banding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

The left heart after pulmonary valve replacement in adults late after tetralogy of Fallot repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.6

Significant left ventricular contribution to right ventricular systolic function.

31 March 2020

1 reference

12 December 2020

Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects

1 reference

12 December 2020

Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.

1 reference

12 December 2020

Pulmonary regurgitation is an important determinant of right ventricular contractile dysfunction in patients with surgically repaired tetralogy of Fallot

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2015.6

1 reference

2 September 2017

1 reference